Rani Therapeutics Inc (RANI) - Forvard P/S multiplikatori
Rani Therapeutics (RANI) biologik inyeksiyalarni almashtirish uchun inqilobiy robotlashtirilgan tabletka ishlab chiqmoqda. Yuqori o'sish potentsiali ushbu noyob texnologiyani royalti evaziga sanoatning yirik ishtirokchilariga litsenziyalash orqali ta'minlanmoqda. Biroq, geosiyosat patent himoyasi va xomashyo logistikasini murakkablashtirmoqda. Biznesning forward P/S ko'rsatkichi bozor kutganlarini aks ettiradi va uning oxirgi qiymati 9.50 deb qayd etilgan bo'lib, bu aktivlarning qadrsizlanishi xavfini baholashga yordam beradi.
Rani Therapeutics Inc (RANI) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- bozor narxi va tahlilchilarning maqsadli narxlari:
- bozor kapitallashuvi ko'rsatkichlari:
- emitentning balans qiymati statistikasi:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning xususiy kapitalga nisbati Rani Therapeutics|RANI - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning o'z kapitaliga nisbati Rani Therapeutics Holdings, Inc.|RANI - Kompaniyaning yig'indi qarzdorligi|Balans kapitallashuviga qarzlar Rani Therapeutics Holdings|RANI - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli qarzlari Rani Therapeutics|Tezkor likvidlik ranitherapeutics.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
RANI - Yakuniy foyda|Prognoz qilingan kelajakdagi foyda Rani Therapeutics|RANI - P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Rani Therapeutics Holdings|RANI - Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|EV/EBITDA multiplikatori RANI|RANI - Foizlar, soliqlar va eskirishdan oldingi foyda|So'nggi 12 oy davomida bir aksiya uchun sof foyda Rani Therapeutics|RANI - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi ranitherapeutics.com|RANI - Joriy yil uchun bitta aksiya uchun sof foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Rani Therapeutics
- sotuvlar va tushum ko'rsatkichlari:
Kompaniyaning umumiy tahlili:Rani Therapeutics Holdings, Inc. RANI
Fundamental xatarlarni minimallashtirish forward P/S koeffitsiyenti tahlilini talab qiladi, u kelajakdagi pul oqimlari uchun to'langan premiumni baholash uchun joriy bozor kapitalizatsiyasini kutilayotgan daromadlar bilan solishtiradi. Rani Therapeutics (RANI) uchun ushbu ko'rsatkich robotlashtirilgan biologik yetkazib berishdagi patent monopoliyasining bozor qiymatini aks ettiradi, bu esa forward P/S koeffitsiyentiga yirik sog'liqni saqlash gigantlariga nisbatan texnologik ustunligining kapitalizatsiya salohiyatini baholash imkonini beradi.
Muhim raqobatchilar
Forvard P/S multiplikatori HLN (Haleon PLC)|Forvard P/S multiplikatori Kenvue Corp KVUE|Verona Pharma PLC - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati jyongbio.com|LGND: Forvard P/S multiplikatori|Kapitalizatsiyaning prognoz qilingan daromadga nisbati AMRX|Narxning prognoz qilingan daromadga nisbati Perrigo Company|Bozor kapitallashuvining kelajakdagi daromadga nisbati Alvotech ALVO|Forvard P/S multiplikatori LQDA|GLPG: Kelajakdagi narxning daromadga nisbati|Forvard P/S multiplikatori ANIP (ANI Pharmaceuticals, Inc.)|Kapitalizatsiyaning kutilayotgan sotuvga nisbati MannKind Corp (MNKD)|AMPH: Forvard narx/daromad multiplikatori|Sotuvga nisbatan forvard narx PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Narxning prognoz qilingan daromadga nisbati|Kapitalizatsiyaning prognoz qilingan daromadga nisbati TBPH|AQST (Aquestive Corp) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori scPharmaceuticals Inc. (SCPH)|Forvard narx/daromad multiplikatori TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati SXT Pharmaceuticals SXTC|Sotuvga nisbatan forvard narx EPRX|BHST - Narxning prognoz qilingan daromadga nisbati|eXoZymes (EXOZ) - Forvard narx/daromad multiplikatori|ORMP: Forvard P/S multiplikatori|ENTX: Narxning kutilayotgan daromadga nisbati|HYFT (ipatherapeutics.com) - Forvard P/S multiplikatori|Forvard P/S multiplikatori ABVC BioPharma|Narxning prognoz qilingan daromadga nisbati Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Bozor kapitallashuvining kelajakdagi daromadga nisbati|SNYR - Narxning prognoz qilingan daromadga nisbati|rallybio.com - Narxning kutilayotgan daromadga nisbati|LEXX: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Pulmatrix Inc|PTHL (Pheton Holdings) - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Aptorum Group Limited APM|Narxning prognoz qilingan daromadga nisbati Lyra Therapeutics (LYRA)|Forvard narx/daromad multiplikatori Impact BioMedical Inc IBO|Narxning prognoz qilingan daromadga nisbati tnfpharma.com TNFA|Sotuvga nisbatan forvard narx YCBD|PainReform Ltd - Forvard P/S multiplikatori|Altamira Therapeutics Ltd (CYTO) - Forvard narx/daromad multiplikatori|lipella.com (LIPO) - Narxning prognoz qilingan daromadga nisbati|OptiNose (OPTN) - Forvard P/S multiplikatori|PIRS (Pieris Pharmaceuticals Inc) - Forvard P/S multiplikatori|PROC: Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati Petros Pharmaceuticals, Inc. (PTPI)|Forvard P/S multiplikatori Qilian International Corp (QLI)|ACELYRIN, Inc. - Forvard narx/daromad multiplikatori|Forvard P/S multiplikatori tffpharma.com TFFP
